Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Irbesartan is a prescription angiotensin II receptor blocker. It treats hypertension and diabetic nephropathy in adults with type 2 diabetes, hypertension, elevated serum creatinine, and proteinuria. Current tablets contain 75 mg, 150 mg, or 300 mg.
read more about irbesartan ...Irbesartan blocks angiotensin II from binding to AT1 receptors in vascular smooth muscle and the adrenal gland. This reduces vasoconstriction and aldosterone-related effects, which lowers blood pressure and changes pressure within the kidneys.
Irbesartan is used for hypertension and for diabetic nephropathy in patients with type 2 diabetes and hypertension who also have elevated serum creatinine and proteinuria above 300 mg per day. Current labeling states that blood pressure reduction was not demonstrated in a study of pediatric patients age 6 through 16.
Hypertension treatment starts at 150 mg once daily and can increase to 300 mg once daily. Diabetic nephropathy uses 300 mg once daily. Patients with marked volume or salt depletion start at 75 mg once daily. Tablets can be taken with or without food.
Irbesartan carries a boxed warning for fetal toxicity and is stopped when pregnancy is detected. Other serious concerns include symptomatic low blood pressure, impaired kidney function, and high potassium. Aliskiren use is contraindicated in patients with diabetes.
Irbesartan treats hypertension and selected diabetic nephropathy in patients with type 2 diabetes and hypertension.
The recommended starting dose is 150 mg once daily.
The recommended dose is 300 mg once daily.
Yes. The boxed warning concerns fetal toxicity.
AVAPRO (Irbesartan) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7885b2a8-be4e-48ab-8113-4e6ab791eb98. Date Accessed October 5, 2026.
Irbesartan. https://www.ncbi.nlm.nih.gov/sites/books/NBK548450/. Date Accessed October 5, 2026.
Irbesartan: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a698009.html. Date Accessed October 5, 2026.
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients With Nephropathy Due to Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/11565517/. Date Accessed October 5, 2026.
The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients With Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/11565519/. Date Accessed October 5, 2026.